Peter J Bartholow
Insider
First SEC filing: Dec. 22, 2003 · Latest: Feb. 14, 2018
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Oct. 20, 2017 | TCBIO | S | 3,500 | $87.52 | $306,320 | 34,171 Direct | -9.29% | Disposed | -78.9% (price as of 2026-10-06) |
| June 2, 2017 | TCBIO | S | 4,000 | $74.52 | $298,080 | 37,671 Direct | -9.60% | Disposed | -75.2% (price as of 2026-10-06) |
| March 22, 2017 | TCBIO | A | 2,931 | · | · | 41,671 Direct | +7.57% | Acquired | (price as of 2026-10-06) |
| Sept. 28, 2016 | TCBIO | A | 5,656 | · | · | 40,240 Direct | +16.35% | Acquired | (price as of 2026-10-06) |
| Jan. 25, 2016 | TCBIO | M | 4,388 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-06) |
| Jan. 25, 2016 | TCBIO | P | 4,000 | $32.80 | $131,200 | 34,584 Direct | +13.08% | Acquired | -43.6% (price as of 2026-10-06) |
| Jan. 25, 2016 | TCBIO | S | 886 | $32.40 | $28,706 | 30,584 Direct | -2.82% | Disposed | -42.9% (price as of 2026-10-06) |
| Jan. 25, 2016 | TCBIO | F | 3,502 | $32.36 | $113,325 | 31,470 Direct | -10.01% | Disposed | -42.8% (price as of 2026-10-06) |
| Jan. 25, 2016 | TCBIO | M | 4,388 | $22.65 | $99,388 | 34,972 Direct | +14.35% | Acquired | -18.3% (price as of 2026-10-06) |
| June 1, 2015 | TCBIO | A | 8,084 | · | · | 30,584 Direct | +35.93% | Acquired | (price as of 2026-10-06) |
| Oct. 28, 2013 | TCBIO | S | 10,000 | $55.22 | $552,200 | 25,000 Direct | -28.57% | Disposed | -66.5% (price as of 2026-10-06) |
| May 17, 2013 | TCBIO | S | 21,781 | $44.32 | $965,334 | 35,000 Direct | -38.36% | Disposed | -58.3% (price as of 2026-10-06) |
| May 16, 2013 | TCBIO | M | 50,000 | $8.25 | $412,500 | 81,349 Direct | +159.49% | Acquired | 124.2% (price as of 2026-10-06) |
| May 16, 2013 | TCBIO | F | 24,568 | $44.36 | $1,089,836 | 56,781 Direct | -30.20% | Disposed | -58.3% (price as of 2026-10-06) |
| May 16, 2013 | TCBIO | M | 50,000 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-06) |
| Jan. 27, 2013 | TCBIO | F | 456 | $42.32 | $19,298 | 31,349 Direct | -1.43% | Disposed | -56.3% (price as of 2026-10-06) |
| Aug. 8, 2012 | TCBIO | S | 10,000 | $43.70 | $437,000 | 31,805 Direct | -23.92% | Disposed | -57.7% (price as of 2026-10-06) |
| June 7, 2012 | TCBIO | S | 4,900 | $38.54 | $188,846 | 51,921 Direct | -8.62% | Disposed | -52.0% (price as of 2026-10-06) |
| June 6, 2012 | TCBIO | F | 2,116 | $38.07 | $80,556 | 56,821 Direct | -3.59% | Disposed | -51.4% (price as of 2026-10-06) |
| April 26, 2012 | TCBIO | S | 7,000 | $36.77 | $257,390 | 50,937 Direct | -12.08% | Disposed | -49.7% (price as of 2026-10-06) |
| March 29, 2012 | TCBIO | F | 2,116 | $35.10 | $74,272 | 55,821 Direct | -3.65% | Disposed | -47.3% (price as of 2026-10-06) |
| March 1, 2012 | TCBIO | S | 2,500 | $34.65 | $86,625 | 57,937 Direct | -4.14% | Disposed | -46.6% (price as of 2026-10-06) |
| Feb. 27, 2012 | TCBIO | F | 2,116 | $33.75 | $71,415 | 73,437 Direct | -2.80% | Disposed | -45.2% (price as of 2026-10-06) |
| Jan. 31, 2012 | TCBIO | S | 3,000 | $31.90 | $95,700 | 64,922 Direct | -4.42% | Disposed | -42.0% (price as of 2026-10-06) |
| Jan. 31, 2012 | TCBIO | S | 2,000 | $31.95 | $63,900 | 62,922 Direct | -3.08% | Disposed | -42.1% (price as of 2026-10-06) |
| Jan. 27, 2012 | TCBIO | F | 369 | $31.64 | $11,675 | 67,553 Direct | -0.54% | Disposed | -41.5% (price as of 2026-10-06) |
| Jan. 13, 2012 | TCBIO | F | 2,243 | $31.73 | $71,170 | 67,922 Direct | -3.20% | Disposed | -41.7% (price as of 2026-10-06) |
| Oct. 27, 2011 | TCBIO | S | 5,000 | $28.63 | $143,150 | 70,165 Direct | -6.65% | Disposed | -35.4% (price as of 2026-10-06) |
| May 18, 2011 | TCBIO | S | 7,000 | $24.50 | $171,500 | 138,377 Direct | -4.82% | Disposed | -24.5% (price as of 2026-10-06) |
| Feb. 22, 2010 | TCBIO | S | 5,000 | $17.01 | $85,050 | 138,261 Direct | -3.49% | Disposed | 8.8% (price as of 2026-10-06) |
| Aug. 12, 2009 | TCBIO | S | 3,783 | $18.05 | $68,283 | 94,929 Direct | -3.83% | Disposed | 2.5% (price as of 2026-10-06) |
| Jan. 27, 2009 | TCBIO | A | 16,720 | · | · | 94,935 Direct | +21.38% | Acquired | (price as of 2026-10-06) |
| Oct. 29, 2008 | TCBIO | S | 5,000 | $16.98 | $84,900 | 78,215 Direct | -6.01% | Disposed | 9.0% (price as of 2026-10-06) |
| Aug. 11, 2008 | TCBIO | S | 3,000 | $17.88 | $53,640 | 83,215 Direct | -3.48% | Disposed | 3.5% (price as of 2026-10-06) |
| May 7, 2008 | TCBIO | S | 1,517 | $18.75 | $28,444 | 86,000 Direct | -1.73% | Disposed | -1.3% (price as of 2026-10-06) |
| May 5, 2008 | TCBIO | S | 1,165 | $19.00 | $22,135 | 87,517 Direct | -1.31% | Disposed | -2.6% (price as of 2026-10-06) |
| April 24, 2007 | TCBIO | A | 734 | · | · | 77,899 Direct | +0.95% | Acquired | (price as of 2026-10-06) |
| April 24, 2007 | TCBIO | F | 265 | $21.27 | $5,637 | 77,165 Direct | -0.34% | Disposed | -13.0% (price as of 2026-10-06) |
| Jan. 30, 2007 | TCBIO | A | 40,000 | · | · | 40,000 Direct | · | Acquired | (price as of 2026-10-06) |
| April 24, 2006 | TCBIO | C | 999 | · | · | 3,992 Direct | -20.02% | Disposed | (price as of 2026-10-06) |
| April 24, 2006 | TCBIO | A | 22,569 | · | · | 22,569 Direct | · | Acquired | (price as of 2026-10-06) |
| April 24, 2006 | TCBIO | A | 4,388 | · | · | 4,388 Direct | · | Acquired | (price as of 2026-10-06) |
| April 24, 2006 | TCBIO | A | 4,991 | · | · | 4,991 Direct | · | Acquired | (price as of 2026-10-06) |
| April 21, 2004 | TCBIO | A | 11,033 | · | · | 19,033 Direct | +137.91% | Acquired | (price as of 2026-10-06) |
| April 21, 2004 | TCBIO | A | 38,750 | · | · | 38,750 Direct | · | Acquired | (price as of 2026-10-06) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 25, 2016 | TCBIO | Stock Appreciation Rights | Common Stock | $22.65 | April 24, 2016 | 4,388 | Disposed |
| May 16, 2013 | TCBIO | Stock Options | Common Stock | $8.25 | July 9, 2013 | 50,000 | Disposed |
| Jan. 30, 2007 | TCBIO | Restricted Stock Units | Common Stock | · | · | 40,000 | Acquired |
| April 24, 2006 | TCBIO | Restricted Stock Units | Common Stock | · | · | 999 | Disposed |
| April 24, 2006 | TCBIO | Stock Apreciation Rights | Common Stock | $22.65 | April 24, 2016 | 22,569 | Acquired |
| April 24, 2006 | TCBIO | Stock Appreciation Rights | Common Stock | $22.65 | April 24, 2016 | 4,388 | Acquired |
| April 24, 2006 | TCBIO | Restricted Stock Units | Common Stock | · | · | 4,991 | Acquired |
| April 21, 2004 | TCBIO | Restricted Stock Units | Common Stock | · | · | 38,750 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 6 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Dec. 22, 2003 | TCBIO | Common Stock [F1] | 8,000 | Direct |
| Oct. 20, 2003 | TCBIO | Common Stock | 8,000 | Direct |
| Oct. 20, 2003 | TCBIO | Common Stock Purchase Options | 10,000 | Direct |
| Oct. 20, 2003 | TCBIO | Common Stock Purchase Options | 10,000 | Direct |
| Oct. 20, 2003 | TCBIO | Common Stock Purchase Options | 10,000 | Direct |
| Oct. 20, 2003 | TCBIO | Common Stock Purchase Options | 10,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2017 | $505,000 | · | · | · | · | · | $54,083 | $1,505,631 |
| 2016 | $478,000 | · | · | · | · | · | $75,262 | $1,640,713 |
| 2015 | $455,333 | · | · | · | · | · | $34,526 | $1,398,849 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.